

CURRICULUM VITAE FOR
AMJAD PARVEZ KHOKHAR, M.D.

SUGARLAND EYE & LASER CENTER, P.A.
736 HIGHWAY 6, #101 · SUGAR LAND, TEXAS 77478
281-240-0478 PHONE · 281-240-0479 FAX

Employment History

5/05-	Sugarland Eye & Laser Center, P.A. <ul style="list-style-type: none">• Medical Director	Sugar Land, TX
7/04 – 5/05	Houston Ophthalmology, P.A. <ul style="list-style-type: none">• Associate in a group practice	Houston, TX

Postgraduate Training

7/01 – 2004	University of Texas Medical Branch <ul style="list-style-type: none">• Resident in Department of Ophthalmology• Recipient of <i>Ophthalmic Knowledge Assessment Program (OKAP)</i> Performance Award	Galveston, TX
6/00 – 6/01	Baylor College of Medicine <ul style="list-style-type: none">• Resident in Transitional Program	Houston, TX

Education

8/96 – 5/00	Baylor College of Medicine <ul style="list-style-type: none">• Medical Degree	Houston, TX
8/93 – 5/96	Rice University <ul style="list-style-type: none">• Magna Cum Laude	Houston, TX

Hospital Privileges

- Memorial Hermann Southwest
- Memorial Herman Sugar Land
- St. Joseph Medical Center
- Oakbend Medical Center
- Triumph Hospital
- Laser Eye Institute
- River Oaks Surgical Center

CURRICULUM VITAE FOR
AMJAD PARVEZ KHOKHAR, M.D.
SUGARLAND EYE & LASER CENTER, P.A.
3531 TOWN CENTER BLVD., #102 · SUGARLAND, TEXAS 77479
PHONE 281-240-0478 · FAX 281-240-0479

Licenses and Certifications

- Board Certified by American Board of Ophthalmology
- Allegretto Wave and Wave Eye-Q Certifications
- VISX Excimer Laser Certification
- Customvue Laser Certification
- Intralase Certification

Memberships

- American Academy of Ophthalmology, Fellow
- Texas Medical Association
- Harris County Medical Society
- Houston Ophthalmologic Society

Research, Presentations, and Publications

Paysse EA, Khokhar A, McCreery KM, Morris MC, Coats DK. Up-slanting palpebral fissures and oblique astigmatism associated with A-pattern strabismus and overdepression in adduction in spina bifida. *Journal of the American Academy of Pediatric Ophthalmology and Strabismus*. 2002 December; 6(6): 354-9.

- Presented at the American Academy of Pediatric Ophthalmology, April 13, 2000, San Diego, CA.
- Presented at the European Strabismological Association, September 26, 1999, Jerusalem, Israel.
- Presented at the James K. Welch Research Symposium, January 12, 2000, Houston, TX
- Presented at the Texas Society of Pediatric Ophthalmology, September 15, 1999, Houston, TX.

Khokhar AP, Lee AG. Case report: optic neuropathy in a patient on IFN alpha for hepatitis C. *Ocular Surgery News*. 2000 May 15; 18(10): 126.

Khokhar AP, Tang R, Wong BR. Bilateral simultaneous temporal artery biopsies in giant cell arteritis. Presented at UTMB 2002 Annual Ophthalmology Meeting. June 8, 2002. Galveston, TX.

Awards

- America's Top LASIK Surgeon Award
- Houston Top Doctor Award
- Ophthalmic Knowledge Assessment Program High Score Award
- Rice University President's Honor Roll: all semesters
- Phi Beta Kappa
- Rice University National Merit Scholarship
- Robert A. Welch Foundation Undergraduate Scholarship
- Citizen's Scholarship Foundation of America Leadership Scholarship

CURRICULUM VITAE FOR
AMJAD PARVEZ KHOKHAR, M.D.
SUGARLAND EYE & LASER CENTER, P.A.
3531 TOWN CENTER BLVD., #102 · SUGARLAND, TEXAS 77479
PHONE 281-240-0478 · FAX 281-240-0479

Research Sub-investigation

- Clinical Trail Networks
- Southwest Houston Research, Ltd., Arlene Bernardo MD, 10850 S Wilcrest Drive, Suite 170-A, Houston, TX 77099, 281- 598-2210, 281-598-2213 (f): “FGCL-SM2216-019: A Phase 2 Randomized, Multi-Center Study of the Safety and Efficacy of xxxxxx in Subjects with Reanl Anemia Nor Requiring Dialysis and Not Receiving Recombinant Human Erythropoeitin”
- Pioneer Research Solutions, Inc., Nuzhat Sayeeduddin (Regulatory Affairs Manager), 6666 Harwin Dr, Ste #130, Houston, TX 77036, 713-333-9323, 713-333-9324 (f): “A 52-week randomized, controlled, open label, multicenter, multinational treat-to-target trial comparing the efficacy and safety of XXX and insulin glargine, both injected once daily in combination with oral anti-diabetic drugs (OAD), in subjects with type 2 diabetes mellitus currently treated with OAD(s) and qualifying for more intensified treatment”